

A systematic review and meta-analysis of Long COVID symptoms

¹Arun Natarajan*, ^{2,3}Ashish Shetty*, ⁴Gayathri Delanerolle*, ⁵Yutian Zeng**, ⁶Yingzhe Zhang**, ⁷Vanessa Raymont, ⁸Shanaya Rathod, ⁹Sam Halabi***, ⁸Kathryn Elliot, ^{8,10}Peter Phiri***, ^{5,11}Jian Qing Shi***

Affiliations

¹Hillingdon Hospital NHS Foundation Trust
²University College London Hospitals NHS Foundation Trust
³University College London
⁴University of Oxford, Nuffield Department of Primary Health Care Sciences
⁵Southern University of Science and Technology
⁶West China Hospital of Sichuan University
⁷University of Oxford, Department of Psychiatry
⁸Southern Health NHS Foundation Trust
⁹O'Neill Institute for National and Global Health Law, Georgetown University
¹⁰University of Southampton, Department of Psychology
¹¹The Alan Turing Institute, London

Shared authorships

First author*
Second author**
Third author***
Last author***

Corresponding author:

Chief Investigator EPIC project
Dr Peter Phiri, PhD
Southern Health NHS Foundation Trust
Research & Innovation Department
Clinical Trials Facility, Moorgreen Hospital
Southampton, SO30 3JB, UK
Email: peter.phiri@southernhealth.nhs.uk
ORCID: 0000-0001-9950-3254

54

55 **Abstract**

56

57

58 **Background:**

59 Ongoing symptoms or the development of new symptoms following a SARS-CoV-2
60 diagnosis has caused a complex clinical problem known as “Long COVID” (LC). This
61 has introduced further pressure on global healthcare systems as there appears to be
62 a need for ongoing clinical management of these patients. LC personifies
63 heterogeneous symptoms at varying frequencies. The most complex symptoms
64 appear to be driven by the neurology and neuropsychiatry spheres.

65

66 **Methods:**

67 A systematic protocol was developed, peer reviewed and published in PROSPERO.
68 The systematic review included publications from the 1st of December 2019-30th
69 June 2021 published in English. Multiple electronic databases were used. The
70 dataset has been analysed using a random-effects model and a subgroup analysis
71 based on geographical location. Prevalence and 95% confidence intervals (CIs)
72 were established based on the data identified.

73

74 **Results:**

75 Of the 302 studies, 49 met the inclusion criteria, although 36 studies were included in
76 the meta-analysis. The 36 studies had a collective sample size of 11598 LC patients.
77 18 of the 36 studies were designed as cohorts and the remainder were cross-
78 sectional. Symptoms of mental health, gastrointestinal, cardiopulmonary,
79 neurological, and pain were reported.

80

81 **Conclusions:**

82 The quality that differentiates this meta-analysis is that they are cohort and cross-
83 sectional studies with follow-up. It is evident that there is limited knowledge available
84 of LC and current clinical management strategies may be suboptimal as a result.
85 Clinical practice improvements will require more comprehensive clinical research,
86 enabling effective evidence-based approaches to better support patients.

87

88

89

90 **Funding:** None

91

92 **Keywords:** Long Covid, Pain, Neuropsychiatry, Neurology, Autonomic Dysfunction,
93 Gastrointestinal

94

95

96

97

98

99

100

101

102

103

104

105 **Introduction**

106 Global experience with a rapidly evolving and advanced strain of the coronavirus
107 have led to over a million deaths since January 2020. The first case of SARS-CoV-2
108 was reported in China around December 2019. Healthcare systems have been
109 under immense pressure to support both SARS-CoV-2 patients and survivors who
110 continue to demonstrate various symptomatologies which appear to impact the
111 overall quality of life and wellbeing. A report from the Center for Disease Control and
112 Prevention (CDC) in the United States reported that patients recovered from SARS-
113 CoV-2 have continuous symptoms of shortness of breath, fatigue, brain fog, cough,
114 chest pain, stomach pain and headache. Bin Cao and colleagues reported that these
115 complications appear to last for at least 6 months thus far (1). Similarly, Carfi and
116 colleagues reported 87.4% of the survivors suffered from a variety of symptoms at
117 post-60 days since the original SARS-CoV-2 diagnosis (2).

118

119 As SARS-CoV-2 survivors continue to share their experiences, clinical researchers
120 hypothesize the continuation of complex symptomatologies for a longer period of
121 time than initially anticipated (3). As a result, several independent authorities
122 have developed Long COVID guidelines, although the consensus continues to
123 change with the changing evidence base from data gathered from patients.
124 Therefore, a universally accepted Long COVID definition is yet to be elaborated,
125 although a general overview is available. One such important guideline set is from
126 the National Institute for Health and Care Excellence (NICE), which stipulates “*Long*
127 *COVID’ (LC) is commonly used to describe symptoms that continue or develop after*
128 *acute SARS-CoV-2 diagnosis post-4 weeks*” (4). The current research landscape
129 exploring LC is also limited due to the varying reports of symptoms identified in

130 clinical datasets that demonstrates it to be a '*moving target*' and it is challenging
131 clinical researchers to guide clinicians on the most optimal steps to pursue when
132 managing the clinical care of these patients. The World Health Organization's (WHO)
133 Novel Coronavirus Pneumonia Emergency Response Epidemiology Team describes
134 LC as *a complex course of illness*. Therefore, pandemic policymaking itself requires
135 evidence-based clinical research along with patient-reported outcomes and clinician
136 experiences to be reported in an effective manner to channel a more holistic
137 approach to optimise long-term clinical management. A key component appears to
138 be the difference in LC symptoms between men and women, as reported by Mathew
139 et al., who demonstrate that these observations are vital to understand, and that at
140 present this is based particularly on clinician experience with limited
141 pathophysiological and aetiology (5).

142

143 In this study, we conducted a meta-analysis of peer-reviewed and published data
144 using a systematic approach to better understand LC from a neurological and
145 neuropsychiatry perspective.

146

147

148 **Methods**

149 A systematic methodology was developed, peer reviewed, and published in
150 PROSPERO (CRD42021235351). The primary aim of this systematic review was to
151 determine the prevalence of LC symptomatologies pertaining to neuropsychiatry,
152 neurology, and pain. The secondary aim was to determine any other infrequently
153 reported symptoms that may influence neuropsychiatry and/or neurology and/or pain

154 diagnosis following LC. The Preferred Reporting Items for Systematic Reviews and
155 Meta-Analysis (PRISMA) was used to report this study.

156

157 *Search strategy*

158 Multiple databases of Embase, Pubmed, Science Direct, and ProQuest were used
159 with multiple MeSH terms such as *nervous system diseases, autonomic central*
160 *nervous system diseases, autonomic diseases, autonomic nervous system*
161 *disorders, disorders of the autonomic nervous system, autonomic nervous system*
162 *diseases, peripheral autonomic nervous system diseases, autonomic peripheral*
163 *nervous system diseases, parasympathetic nervous system diseases, sympathetic*
164 *nervous system diseases, headaches, migraine, headache after mental exertion,*
165 *exertional headache, tension headache, cluster headache, intra cranial*
166 *hypertension, temporal headache, retro-orbital headache, cervicogenic headache,*
167 *chronic pain, fibromyalgia, back pain, erythromelalgia, endometriosis, intercostal*
168 *neuralgia, leg pain, neuropathic pain, chronic pelvic pain, sciatica, muscle fatigue,*
169 *metal fatigue, cognition, apathy, sleep arousal, sleep deprivation, sleep initiation and*
170 *maintenance, anxiety, depression emotional lability.*

171

172 All studies and surveys were included in the Preliminary R1 round. The reviews and
173 metaanalysis identified were scrutinized for references that can be included in our
174 metaanalysis. A final set was arrived at looking at the possible relevance of the
175 studies comprising of 302 studies. This was analysed as per PRISMA diagram in
176 Figure 1 in the Results section.

177

178

179 *Eligibility criteria*

180 In this meta-analysis, we looked at persistent symptoms in COVID patients, including
181 cohort and cross-sectional studies. All studies included were reported in English.

182

183 *Data extraction and synthesis*

184 Screening and data extraction were performed by four independent reviewers. Any
185 disagreements were discussed and reached a consensus by two reviewers. To fully
186 investigate the impact of LC on the physical health of survivors, we grouped all
187 reported symptoms into five main categories: general symptoms (which includes
188 pain and other infrequently reported symptoms), neurological, mental disorders,
189 cardiopulmonary, and obstetric problems.

190

191 Data extractions were made via studies that included SARS-CoV-2 survivors that
192 had either been hospitalized or treated as outpatients. Therefore, these patients had
193 a confirmed positive test for SARS-CoV-2 in addition to relevant symptoms. All
194 studies that did not report on follow-up data were excluded. For studies that reported
195 on a control and patient group, only the patient data was extracted and used. A data
196 extraction sheet specific to the clinical question of this study was developed. This
197 Excel spreadsheet included study type, sample size, country, characteristics,
198 information, outcomes, duration of symptoms, and prevalence.

199

200 *Risk of bias assessment*

201 A quality assessment was performed using the Newcastle-Ottawa Scale (NOS)
202 (Table 1a) to critically appraise the literature included within the systematic review
203 using common variables. Methodological quality and risk of bias was assessed by

204 independent reviewers according to the NOS, which has validity for use in cohort
205 studies (6) and the adapted version (7) for cross-sectional studies. The scale
206 consists of eight items with three quality parameters: (i) selection, (ii) comparability,
207 and (iii) outcome. We scored the quality of the studies (poor, fair, and good) by
208 allocating stars to each domain as stated below:

- 209 • A **Poor** quality score was allocated 0 or 1 star(s) in selection, 0 stars in
210 comparability, and 0 or 1 star(s) in the outcomes domain
- 211 • A **Fair** quality score was awarded, 2 stars in selection, 1 or 2 stars in
212 comparability, and 2 or 3 stars in outcomes.
- 213 • A **Good** quality score was awarded, 3 or 4 stars in selection, 1 or 2 in
214 comparability, and 2 or 3 stars in outcomes. (6)

215

216 [Table 1a]

217

218 *Data analysis*

219 A random-effects model with an inverse variance method was used for the meta-
220 analysis and the heterogeneity was assessed by I^2 . A subgroup analysis was
221 conducted in terms of study geographical location on the symptoms that were
222 reported in more than 10 studies. Sensitivity analysis was used to test the
223 robustness of the results. Funnel plots and Egger's tests for symptoms with more
224 than 10 studies would be analyzed to detect publication bias. All data analysis will be
225 carried out using R and STATA 15.

226

227

228

229 **Results**

230 Of the 302 studies identified, 49 met the inclusion criteria. 36 studies were included
231 in the final meta-analysis. This was reported within the PRISMA document as
232 demonstrated in Figure 1.

233

234 The 36 studies included comprised of a total sample size of 11,598 people. Of the 36,
235 50% were cohort studies and the remainder cross-sectional. The longest follow-up
236 time among the 36 studies was 8 months, although the most common follow-up time
237 was 4 months. The 36 studies covered multiple geographical locations, where 19
238 countries reported five primary classifications of symptomatology of general clinical,
239 neurological, neuropsychiatry, and cardiopulmonary. Primary clinical features within
240 these categories included fatigue, cognitive impairment, joint pain, anxiety, and
241 depression. These appear to align with the present understanding of LC
242 symptomatology. Study-based characteristics and outcomes are demonstrated in
243 Table 1b.

244

245 [Table 1b]

246 [Figure 1]

247

248 *Meta-analysis*

249 The meta-analysis included 36 studies, which are summarized in Figure 2.

250

251 [Figure 2]

252

253

254 *Categorization:*

255 *General symptoms*

256 General symptoms included those associated with pain (such as general pain,
257 muscle or joint pain, and mobility dysfunction), fatigue, fever, hair fall, skin rash, and
258 weight loss. The pooled prevalence of the general problem was 14.4% with a 95%CI
259 of 11.63% to 17.81%. A forest plot for general symptoms is shown in Figure 2.1.

260

261 [Figure 2.1]

262

263 Fatigue was the most frequently reported symptom within the general problem
264 category. Twenty-one of the thirty-six studies reported fatigue symptoms and the
265 pooled prevalence of fatigue was 29.2% with a 95%CI of 21.59% to 39.45%. Muscle
266 pain was the second most prevalent symptom reported among the 13 studies, which
267 led to a pooled prevalence of 13.30% with a 95%CI of 7.48% to 23.67%. However,
268 the prevalence rate of muscle pain is not as high as some of the other symptoms
269 associated within the generalized category.

270

271 The pooled prevalence of joint pain and hair fall were 28.25% (95%CI 14.76% to
272 54.05%) and 20.29% (95%CI 10.56% to 38.98%) respectively. It appears that the
273 prevalence of these two symptoms were high, but only a few studies mentioned
274 these in comparison to those reporting fatigue and muscle pain. Therefore, it is worth
275 standardizing these variables across all studies to manage a better understanding of
276 the clinical relevance.

277

278

279 *Neurological symptoms*

280 The neurological symptoms included headache, cognitive impairment, and loss of
281 smell, taste, and hearing. As shown in Figure 2.2, the most frequently reported
282 neurological problems were loss of smell and taste, and headache. The pooled
283 prevalence for loss of smell or taste and both taste and smell as well as headaches
284 were 14.76%, 11.98%, 18.05%, and 10.45% respectively. However, the most
285 prevalent neurological symptom reported appears to be cognitive impairment with a
286 pooled prevalence of 28.85% with a 95%CI of 9.99% to 83.18%. The 95% CI is wide,
287 and the identified heterogeneity based on I^2 was 91%. Despite the high
288 heterogeneity, only 3 studies mentioned the symptoms of cognitive impairment.
289 Further studies and improved sampling would be required to demonstrate a more
290 precise statistical conclusion in regard to cognitive impairment and LC.

291

292 [Figure 2.2]

293

294 *Mental health symptoms*

295 Four symptoms, and mental health (MH) symptoms including depression, anxiety,
296 PTSD, and sleep disturbances, were reported within the neuropsychiatry category.
297 The pooled results can be found in Figure 2.3. The collective prevalence of MH
298 symptoms was 21.26% (95%CI 16.81% to 26.9%), while each symptom
299 independently also demonstrated a high prevalence. Anxiety prevalence was
300 identified to be 27.77% with a 95%CI of 16.56% to 46.53%, while the prevalence of
301 depression was 22.44% (95%CI 10.22% to 49.35%). The pooled prevalence of
302 studies reporting patients with both anxiety and depression was 23.45% (95%CI
303 19.79% to 27.8%). The prevalence of sleep disturbance was identified to be 19.13%

304 with a 95%CI of 12.44% to 29.43%. This is an important facet to demonstrate given
305 that there is a large number of studies demonstrating depression and anxiety to be
306 the most commonly reported MH outcomes among SARS-CoV-2 patients.

307

308 [Figure 2.3]

309

310 *Cardiopulmonary symptoms*

311 LC patients demonstrated cardiopulmonary symptoms with 5 commonly reported
312 issues of chest pain, sore throat, dyspnea, palpitations, and cough. As can be seen
313 from Figure 2.4, dyspnea appeared to have the highest prevalence with 17 of 36
314 studies reporting it as a primary end point. The pooled prevalence was therefore
315 21.48% with a 95%CI of 14.37% to 21.2%. Cough was the second most commonly
316 reported symptom across 14 of 36 studies. The pooled prevalence was 17.83% with
317 a 95%CI of 13.34% to 23.86%.

318

319 [Figure 2.4]

320

321 *Gastrointestinal symptoms*

322 The overall prevalence of gastrointestinal problems, as shown in Figure 2.5, was
323 6.22% with a 95%CI of 4.61% to 8.39% and is comparatively minimal to the other
324 categorical symptoms identified. Commonly reported symptoms reported in this
325 category were poor appetite, diarrhea and emesis, diarrhea or emesis, nausea, and
326 abdominal pain. Diarrhea and emesis had the highest prevalence of 14.64% with a
327 95%CI of 1.72% to 124.46%. Studies about diarrhea/emesis were too small. Only

328 two studies mentioned diarrhea and emesis, which also indicated a high
329 heterogeneity with an $I^2 = 97.9\%$.

330

331 [Figure 2.5]

332

333 *Subgroup analysis*

334 A subgroup analysis was conducted based on geographical regions correlated with
335 the 8 symptoms of fatigue, headache, cough, loss of smell and taste, dyspnoea,
336 chest, and muscle pain (see Figure 3).

337

338 [Figure 3]

339

340 High prevalence of each symptom was reported by the studies from North America
341 (mainly USA), followed by the Middle East and Australia. Most of the symptoms had
342 a lower prevalence in Africa and Asia. Due to the small number of studies in the
343 subgroup, the conclusions may have bias; for this reason, data from one subgroup
344 was of concern to us. 10 studies from Europe reported dyspnoea in this subgroup
345 and the pooled prevalence of this subgroup was 30.87% with 95%CI of 20.18% to
346 41.55%, which was the second highest prevalence among different regions. This
347 suggested that dyspnoea was a highly prevalent symptom in European countries
348 and should be addressed by the healthcare system to improve post-discharge care.

349

350 Funnel plots of the eight symptoms identified were reported in Figure 4. It is
351 apparent, based on the funnel plots, there is the presence of high heterogeneity.

352 Many studies were outside the scope of 95% CI, so it was difficult to intuitively detect
 353 the bias. Therefore, Egger’s test was used to determine publication bias.

354

355 [Figure 4]

356

357 *Sensitivity analysis*

358 Many studies were outside the 95% confidence interval as demonstrated within the
 359 funnel plots, which could impact the overall conclusions of this study. Therefore, a
 360 sensitivity analysis was conducted to determine the consensus of the overall
 361 conclusion of the study. A Copas selection model was used (8,9) to adjust the
 362 pooled prevalence, as demonstrated in Table 2.

363

364

365 **Table 2: Summarized results of sensitivity analysis**

Phenotype	N of study	Model	Probability of publishing study with largest standard error	Proportion(%)	lower(%)	upper(%)	p-value for differences between two conclusions
headache	14	copas selection model	49.55%	13.4637	10.0332	18.0672	0.1135
		random effects model		9.4972	4.8842	18.4673	
smell dysfunction	18	copas selection model	100.00%	14.1682	10.1188	19.8380	0.5006
		random effects model		14.3823	11.3816	18.1741	
taste dysfunction	12	copas selection model	100.00%	12.2338	8.2962	18.0402	0.5495
		random effects model		12.3296	9.0703	16.7601	
chest pain	11	copas selection model	100.00%	12.4236	7.2232	21.3681	0.103
		random effects model		12.1217	6.1288	23.9508	
dyspnea	17	copas selection model	100.00%	21.5591	15.1515	30.6797	0.1819
		random effects model		21.4774	14.368	32.1046	
cough	14	copas selection model	91.11%	18.176	12.8109	25.7852	0.1238
		random effects model		17.8321	13.3431	23.8551	
fatigue	21	copas selection model	92.46%	29.1951	21.5850	39.4487	0.1478
		random effects model		28.9161	20.3158	41.1531	
muscle pain	13	copas selection model	67.65%	15.6426	9.1963	26.6103	0.1038
		random effects model		13.3031	7.4783	23.6651	

366

367

368 In Table 2, the proportion of selected studies varied, and the changes in the P-value
369 of the residual selection bias are depicted in Figures 5 (1)-(8). The Copas model
370 (CSM) was used to determine bias within studies based on P-values exceeding 0.1.
371 The proportion of studies used within the CSM are listed within Table 2. It is evident
372 the CSM selected 49.55% studies with headache as a symptom, while the remaining
373 50.45% indicated a significant standard error, demonstrating poor quality and high
374 heterogeneity, thus were excluded.

375

376 The result from the CSM was compared to a random effects model (REM), indicating
377 P-values exceeding 0.05, which demonstrates a lack of statistical significance.
378 Therefore, the results of this study are consistent and provide robust conclusions.

379

380 [Figure 5 (1)-(8)]

381

382 *Publication bias*

383 Egger's test was used to determine publication bias. The P-values were calculated
384 based on Egger's test.

385

386 **Table 3: Summarized P-values of Egger's tests for symptoms with more than**
387 **10 studies**

388

Phenotype	Number of studies	P-value of Egger's test
General problems		
fatigue	21	0.14
muscle pain	13	0.093
Neurological problems		
Smell loss	18	0.616
Taste loss	12	0.517
headache	14	0.022
Cardiopulmonary problems		

Chest pain	11	0.048
dyspnea	17	0.007*
cough	14	0.085

389

390 Note: (*) : $p < 0.05$ indicates significance

391

392 As shown in Table 3, studies reporting symptoms of headache and dyspnea have
393 significant bias, with P-values of 0.022 and 0.007 respectively. Therefore, the pooled
394 prevalence of headache and dyspnea were 9.5% and 21.48%. In Figures 4(2) and
395 (3), the prevalence of headache and dyspnea may have been underestimated, and
396 more studies should be found to further confirm the conclusions.

397

398 [Figure 4(2) and 4(3)]

399

400 **Limitations**

401 There are strengths and weaknesses to our study given that comparing patients with
402 maximum symptoms risks bias reporting. Studies that reported on neuropsychiatry
403 symptoms of depression and anxiety, for example, did not demonstrate a clinical
404 diagnosis. The identified and reported features cannot be deemed to be LC as these
405 patients could have underlying conditions that may not have been reported. Patients
406 who may have had critical respiratory illness, for example, may have been part of
407 these studies, but this data was not captured within the original peer-reviewed
408 publications. This would influence the analysis conducted within our study; therefore,
409 an underrepresentation and/or overrepresentation of some of these symptoms is a
410 point to consider.

411

412

413

414

415

416 **Discussion**

417 This meta-analysis demonstrates the most recent studies identified with possible
418 long COVID symptoms. The pooled data indicate both self-reported and clinically
419 reported symptoms. This initial step is vital to design and develop comprehensive
420 research in the future, especially since SARS-CoV-2 appears to be reporting a
421 varying degree of symptoms.

422

423 The evidence identified demonstrates that long COVID appears to have multiple
424 symptoms, without clear aetiology similar to fibromyalgia and chronic fatigue
425 syndrome. The forementioned conditions also have an association with postviral
426 illness which appear to last longer than previously anticipated. As a result,
427 healthcare systems endeavour challenges with draining resources and souring costs
428 in addition to wellbeing concerns for staff. Another direct result of long COVID
429 disease will be the added burden on waiting times for patients requiring other clinical
430 care and elective procedures created by the pandemic.

431

432 The population prevalence of long COVID identified here could be used to determine
433 symptom-based models to evaluate the requirement for healthcare system
434 resources, and possible disease sequelae which may require care. Presently,
435 instituting effective therapies is based upon present clinical knowledge than
436 evidence-based practices. Repurposing drugs is another common theme among
437 clinicians, and these raise concerns around long COVID potentially becoming a
438 chronic condition in the near future, especially for patients who had significant issues

439 with COVID. With a growing number of variants of SARS-Cov-2 virus, this further
440 exacerbates the present unknowns of managing these patients in an optimal
441 manner. However, this meta-analysis does provide an opportunity to plan early
442 intervention strategies and target therapies in the future.

443

444 As it is an evolving pathology, further studies are being reported and published
445 swiftly, which has its own challenges. Therefore, to consistently report the latest
446 evidence, there is a requirement for a *living systematic review and meta-analysis* as
447 well as better methodologies should be developed. It is interesting to note that
448 developed countries appear to have a higher incidence of long COVID based on the
449 geographical data identified within this study. There is a possibility of over- and
450 under reporting, as well as validation of self-reported data. The lack of accurate
451 validated measurements for reported long COVID symptoms similar to other
452 fundamental clinical measures such as blood pressure and temperature causes
453 further problems.

454

455 In addition to these factors, ethical and moral implications to patients, the public, and
456 healthcare professionals continue to augment debates as the pandemic has forced
457 all stakeholders to rethink access to healthcare and treatment.

458

459 It is evident from this study that there are post-COVID symptoms that patients
460 continue to report. It might be beneficial to reduce the severity of the disease. A
461 useful method to reduce these of course would be to increase the vaccination
462 program outputs globally. With mass migration also attributed to the spread of Covid-
463 19, an important facet to consider would be to understand the barriers and potential

464 issues around vaccine acceptability, especially for those returning to work or their
465 education in countries of residence.

466 The COVAX Facility is an international collaborative effort shared between the
467 Coalition for Epidemic Preparedness Innovations (CEPI), the Global Alliance for
468 Vaccines and immunizations (GAVI), the World Health Organization, supporting
469 governments and international organizations. (10) The COVAX Facility is meant to
470 facilitate the development and production of diagnostics, therapeutics, and vaccines
471 to combat the COVID-19 pandemic and to make them accessible to LMIC
472 governments. (11,12) The COVAX Facility does not have a legal
473 entity, therefore cannot enter into binding agreements, and relies upon agreements
474 between its constituent partners (e.g. GAVI, WHO) procuring government, and the
475 vaccine manufacturers. (13) Therefore, the law of contract governs access to
476 vaccines, data related to vaccine procurement and distribution, and related matters.

477 Similarly, sharing of data to better assess the mental and physical health sequelae
478 has been hampered by the lack of an international coordinating mechanism to do so
479 or a uniform set of guidelines that governments, public health officials, private
480 companies, and others may use to share such data. (14) As a result, COVID data
481 related to incidence, disease burden, and long COVID as well as a potential disease
482 sequelae may not be fully understood by the global healthcare community. This is a
483 particular a problem for assessing both COVID and long COVID syndrome impact on
484 differing ethnicities, age groups, and overall health status. Even within academic and
485 clinical research, only open access publications provide insight into evidence.

486

487 The justification of resources being reallocated to non-life-threatening sequelae of
488 long COVID could be a contentious topic. This further raises legal implications for
489 policymakers.

490

491 The research on nociplastic and immunological explanations for pain symptoms
492 could throw more light in future on the development of pain with long
493 COVID. Genetic studies may also throw some light into the development of long-
494 standing chronic pain or even long COVID, although this requires bio-sampling at a
495 high frequency. The role of nutritional status and activity levels also needs to be
496 established and its association with long COVID needs further study.

497

498

499 **Conclusions**

500 A key finding of this study is that the speed at which SARS-CoV-2 research is being
501 conducted has meant epistemic authority consolidates around particular clinical
502 areas. Therefore, it is vital to synthesise the evidence without any background noise.
503 However, as demonstrated in this study, the gathering of LC data has been limited.
504 The identified data could be associated with autonomic dysfunction, although to
505 confirm this, further investigations would be required. Mapping LC outcomes would
506 be a long-term commitment; therefore, future systematic reviews and meta-analysis
507 should be reported in a *living* format, combining both clinical and research data to
508 allow a more comprehensive synthesis of evidence with a view to using surveillance
509 data.

510

511

512

513 **List of abbreviations**

514

515 **CI:** confidence interval

516 **CSM:** Copas selection model

517 **GAVI:** Global Alliance for Vaccines and Immunizations

518 **LC:** Long-Covid

519 **MH:** Mental health

520 **NOS:** Newcastle-Ottawa Scale

521 **PRISMA:** Preferred Reporting Items for Systematic Reviews and Meta-Analysis

522 **REM:** Random effects model

523 **WHO:** World Health Organization

524

525

526

527

528 **Declarations**

529

530 **Ethics approval and consent to participate**

531 Not applicable

532

533 **Consent for publication**

534 Not applicable

535 **Availability of data and materials**

536 All data used within this study have been publicly available. The authors will consider
537 sharing the dataset gathered upon request.

538

539 **Competing interests**

540 PP has received a research grant from Novo Nordisk, and the other, educational
541 from Queen Mary University of London, from John Wiley & Sons, and other from
542 Otsuka, outside the submitted work. SR reports research funding associated with
543 other studies from Janssen, Otsuka, and Lundbeck. AS reports funding associated
544 with other projects from Medtronic. GD reports research funding associated with
545 NIHR RCF. VR reports funding associated with other studies from the Medical
546 Research Council.

547

548 This research is based on evidence gathered systematically and has not been
549 influenced unduly by expertise.

550

551 All other authors report no conflict of interest.

552

553 The views expressed are those of the authors and not necessarily those of the NHS,
554 the National Institute for Health Research, Department of Health and Social Care
555 or Academic institutions.

556

557 **Funding**

558 KE and GD are supported by National Institute for Health Research (NIHR)
559 Research Capability Funding (RCF) and by Southern Health NHS Foundation Trust.
560 All study sponsors had no further role in the study design, data collection, analysis,
561 and interpretation of data; in the writing of the report and in the decision to submit the
562 paper for publication

563

564 **Authors' contributions**

565 PP and GD developed study design and GD wrote the first draft of the manuscript.
566 AN conducted database searches and study selection and data extraction. YZ, JQS,
567 GD performed statistical analyses and contributed to the results' section. AN, AS,
568 GD, YE, YZ, DK, VR, SR, SH, KE, JQS and PP critically reviewed and revised the
569 manuscript. All authors approved the final version of the manuscript.

570

571 **Acknowledgements**

572 The authors acknowledge initial contributions made by Dr M Sam Chong, Dr Robert
573 Shane Delamont and Dr Mayur Bodani. We would like to acknowledge Professor
574 Balakrishna Shetty for providing us his thoughts on Covid and Long-covid as a
575 practicing physician managing the ongoing care of patients.

576

577 This paper is part of the multifaceted EPIC project, sponsored by Southern Health
578 NHS Foundation Trust and in collaboration with the University of Oxford, University
579 College London, University College London NHS Foundation Trust and Southern
580 University of Science and Technology (China).

581

582

583

584

585 **References**

586

587 (1) Centers for Disease Control and Prevention. Post-COVID Conditions. 2021.
588 <https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects.html>.

589

590 (2) The Lancet. Facing up to long COVID. Lancet. 2020;396:1861.

591

592 (3) Carfi A, Bernabei R, Landi F, for the Gemelli Against COVID-19 Post-Acute Care
593 Study Group. Persistent symptoms in patients after acute COVID-19. JAMA.
594 2020;324:603-605.

595

596 (4) National Institute for Health and Care Excellence (NICE), COVID-19 rapid
597 guideline: managing the long-term effects of COVID-19. 2020.

598 www.nice.org.uk/guidance/ng188.

599


- 600 (5) Darley DR, Dore G, Byrne A, Plit M, Brew BJ, Kelleher AD, Matthews GV. Limited
601 recovery from post-acute sequelae of SARS-CoV-2 (PASC) at eight months of a
602 prospective cohort. medRxiv [Preprint] 2021.
603
- 604 (6) Wells G, Shea B, O'Connell D, Peterson J, Welch V, Loso M, Tugwell P. The
605 Newcastle-Ottawa Scale (Nos) for Assessing the Quality of Nonrandomised Studies
606 in Meta-Analyses. Ottawa, Canada: Ottawa Hospital Research Institute; 2000.
607
- 608 (7) Modesti PA, Reboldi G, Cappuccio FP, Agyemang C, Remuzzi G, Rapi S,
609 Perruolo E, Parati G, ESH Working Group on CV Risk in Low Resource Settings.
610 Panethnic Differences in Bloody Pressure in Europe: A Systematic Review and
611 Meta-Analysis. PloS One. 2016;11:e0147601. doi:10.1371/journal.pone.0147601.
612
- 613 (8) Copas J, Shi JQ. Meta-analysis, funnel plots and sensitivity
614 analysis. Biostat. 2000;1:247-262.
615
- 616 (9) Copas JB, Shi JQ. A sensitivity analysis for publication bias in systematic
617 reviews. Statistical Methods in Med Res. 2001;10:251-265.
618
- 619 (10) Berkley S. COVAX explained. 2020. [www.gavi.org/vaccineswork/covax-](http://www.gavi.org/vaccineswork/covax-explained)
620 [explained](http://www.gavi.org/vaccineswork/covax-explained).
621
- 622 (11) Lurie N, Gilbert N, Hamburg M, Hoyt K, Morrison JS. The Scramble for Vaccines
623 and the COVAX Facility. [Online event] Center for Strategic and International
624 Studies. 11th August 2020.
625
- 626 (12) Gavi. Donor profiles. 2020. www.gavi.org/investing-gavi/funding/donor-profiles.
627
- 628 (13) Halabi S. Solving the Pandemic Vaccine Product Liability Problem. UC Irvine
629 Law Rev. 2021.
630
- 631 (14) Fegan G, Cheah PY, Data Sharing Working Group. Solutions to COVID-19 data
632 sharing. Lancet Digital Health. 2021;3:e6.
633
634
635
636

637 **Figure titles & legends**

- 638
- 639 **Figure 1:** PRISMA Flow Diagram
640 **Figure 2:** Summary of studies included in meta-analysis
641 **Figure 2.1:** Forest plots for general symptoms
642 **Figure 2.2:** Forest plots for neurological symptoms
643 **Figure 2.3:** Forest plots for mental health symptoms
644 **Figure 2.4:** Forest plots for cardiopulmonary symptoms
645 **Figure 2.5:** Forest plots for gastrointestinal symptoms
646 **Figure 3:** Forest plots of subgroup analysis
647 **Figure 4:** Funnel plots of eight symptoms (reported in more than 10 studies)
648 **Figure 5:** P-values for residual selection bias
649


650
651
652
653
654
655
656
657
658
659
660
661
662
670
671
679
680
688
689
698

Figure 1: PRISMA Flow Diagram




699
700
701
702
703
704
705
706
707
708
709
710

Figure 2: Summary of studies included in meta-analysis




711
712

Figure 2.1: Forest plots for general symptoms




713
714
715

Figure 2.2: Forest plots for neurological symptoms




716
717
718
719
720
721
722

Figure 2.3: Forest plots for mental health symptoms




723
724
725

Figure 2.4: Forest plots for cardiopulmonary symptoms




726
727
728
729
730
731
732

Figure 2.5: Forest plots for gastrointestinal symptoms



733
734
735
736
737
738
739
740
741


Figure 3: Forest plots of subgroup analysis
(1)Fatigue (2)Headache




742
743
744
745
746
747
748
749
750
751
752

(3)Dyspnea (4) Cough

753
754




(5) Smell dysfunction




(6) Taste dysfunction

755
756




(7) Chest pain




(8) Muscle pain

757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772




(1) Fatigue




(2) Headache

773
774




(3)Dyspnea




(4) Cough

775
776




(5)Smell dysfunction




(6) Taste dysfunction

777
778



(7)Chest pain



(8) Muscle pain

779
780





Figure 5: P-values for residual selection bias

781
782
783
784
785
786
787
788
789
790
791


(1) Fatigue

(2) Headache




792
793
794
795

(3) Dyspnea




(4) Cough




796
797
798
799
800

(5) Smell dysfunction




(6) Taste dysfunction




801
802
803
804

(7) Chest pain



(8) Muscle pain

805



806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842

843 **Tables**

844

845 **Table 1a [line 216]: Risk of bias quality assessment**

846

	Selection (S)				Comparability (C)		Exposure/Outcome (E/O)			Sub Total assessment			Conclusion	Quality Assessment NOS
	1	2	3	4	1a	1b	1	2	3	S ⁺	C ^{&}	E/O [*]		
Akter et al	*	NO	*	*	*	*	*	*	*	Good	Good	Good	Good	7
Huang et al	*	NO	*	*	NO	*	*	*	*	Good	Good	Good	Good	6
Humphreys et al	*	NO	*	NO	*	NO	NO	*	*	Fair	Good	Good	Fair	5
Simani et al	*	NO	*	*	NO	*	*	*	*	Good	Good	Good	Good	6
Taylor et al	*	NO	*	*	NO	*	*	*	*	Fair	Good	Fair	Fair	6
Felipe et al	NO	NO	*	*	*	*	*	*	*	Fair	Good	Good	Good	6
Hopkins et al	*	NO	*	*	*	*	*	*	*	Good	Good	Good	Good	7
Petersen et al	*	NO	*	*	*	*	*	*	*	Good	Good	Good	Good	7
Iqbal et al	*	*	*	*	*	*	*	*	*	Good	Good	Good	Good	8
Poncet-Megemont et al	*	*	*	*	*	*	*	*	*	Good	Good	Good	Good	8
Trevisan et al	*	*	*	*	*	*	*	*	*	Good	Good	Good	Good	7
Klein et al	*	NO	*	NO	*	NO	*	NO	NO	Fair	Good	Poor	Poor	4
Munro et al	*	NO	NO	*	NO	NO	*	NO	NO	Fair	Poor	Fair	Poor	4
Chopra et al	*	NO	*	*	NO	NO	*	NO	NO	Good	Poor	Fair	Fair	5
Putri et al	*	NO	*	*	*	*	*	*	*	Good	Good	Good	Good	7
Liu et al	*	NO	*	*	*	*	*	NO	NO	Good	Good	Fair	Good	6
Tenforde et al	*	*	*	*	*	*	*	*	*	Good	Good	Good	Good	8
Sykes et al	*	NO	*	*	*	*	*	*	*	Good	Good	Good	Good	6
Townsend et al	*	NO	*	*	NO	*	*	*	*	Good	Fair	Good	Good	7
Writing Committee for the COMEBAC study group, 2021	*	NO	*	*	*	*	*	NO	NO	Good	Good	Fair	Fair	5
Augustin et al	*	NO	*	*	*	*	*	*	*	Good	Good	Good	Good	6
Duncan et al	*	NO	*	NO	*	*	*	NO	NO	Fair	Good	Fair	Fair	4
Osikomaiya et al	*	NO	*	*	*	*	*	*	*	Good	Good	Good	Good	6
Orrù et al	*	*	*	*	*	*	*	*	*	Good	Good	Good	Good	7
Pujari et al	*	NO	*	NO	*	*	*	*	*	Fair	Good	Good	Good	6
Frontera et al	*	*	*	*	*	*	*	*	*	Good	Good	Good	Good	7
Holmes et al	*	*	*	*	*	*	*	*	*	Good	Good	Good	Good	7
Townsend et al	*	NO	*	NO	*	*	*	NO	NO	Fair	Good	Fair	Fair	4
Estiri et al	*	NO	*	*	*	*	*	NO	NO	Good	Good	Fair	Fair	5
Chevinsky et al	*	NO	*	*	*	*	*	NO	*	Good	Good	Good	Good	6
Pereira et al	*	NO	*	*	*	*	*	NO	NO	Good	Good	Fair	Fair	6
Romero-Duarte et al	*	NO	*	*	*	NO	*	NO	NO	Good	Fair	Fair	Fair	5
Graham et al	*	NO	*	*	*	*	*	*	*	Good	Good	Good	Good	7
Trinkmann et al	*	*	*	*	*	*	*	*	*	Good	Good	Good	Good	7
Nguyen et al	*	NO	*	*	*	NO	*	NO	NO	Good	Fair	Fair	Fair	5
Vrillon et al	*	NO	*	*	*	*	*	*	*	Good	Good	Good	Good	7
Modi et al	*	NO	*	*	*	NO	*	NO	NO	Good	Fair	Fair	Fair	4
Pasquini et	*	NO	*	*	*	*	*	NO	NO	Good	Good	Fair	Good	5

al	*	NO	NO	*	*	*	*	NO	NO	Fair	Good	Fair	Fair	5
Boscolo-Rizzo et al	*	NO	*	*	NO	*	*	NO	NO	Good	Fair	Fair	Fair	4
Capelli et al	*	*	*	*	*	*	*	*	*	Good	Good	Good	Good	7
Yvonne et al	*	*	*	*	*	*	*	*	*	Good	Good	Good	Good	7
Raman et al	*	*	*	*	*	*	*	*	*	Good	Good	Good	Good	6
Swapna Mandal et al	*	*	*	*	*	*	*	*	*	Good	Good	Good	Good	6
Woo et al	*	NO	*	*	*	*	*	*	*	Good	Good	Good	Good	6
Puntmann et al	*	NO	*	*	*	NO	*	*	*	Good	Fair	Good	Good	5
Bellan et al	*	*	*	*	*	*	*	*	*	Good	Good	Good	Good	7
Stavem et al	*	NO	*	*	*	*	*	*	*	Good	Good	Good	Good	6
Malek et al	*	NO	*	*	NO	*	*	NO	NO	Good	Fair	Fair	Fair	5
Printza et al	*	NO	*	NO	*	*	*	NO	NO	Fair	Good	Fair	Fair	4

847
848
849
850
851

Table 1b [line 245]: Characteristics of studies included in meta-analysis

First Author	Publication year	Study type	Sample size	Country	Percent of Women	Ethnicity	follow-up time, months	p-value
Akter	2020	cross-sectional study	734	Bangladesh	24%	/	1	/
Huang	2021	cohort study	1733	China	48%	/	5	/
Humphreys	2021	qualitative study	18	UK	50%	55.6% white 16.7% white other 16.7% Asian 5.6% black 5.6% mixed	1	/
Simani	2021	cross-sectional study	120	Iran	33.3%	/	6	/
Taylor	2021	qualitative study	13	UK	84.6%	84.6% white British	/	/
Felipe	2020	cross-sectional study	46	Brazil	54.3%	/	4	/
Hopkins	2020	cohort study	382	UK	74.6%	/	1	loss of smell p<0.001
Petersen	2020	cohort study	180	Faroe Islands	54.4%	/	4	/
Iqbal	2021	cross-sectional study	158	Pakistan	55.1%	/	1	/
Poncet-Megemont	2020	cohort study	139	France	62.6%	/	1	/
Trevisan	2021	observational study	1618	Italy, Spain and Norway	55%	/	6	/
Klein	2021	cohort study	103	Israel	37.9%	/	6	/
Munro	2020	cross-sectional study	138	UK	12.5%	/	/	/
Chopra	2020	cohort study	488	USA	/	51.6% Black 37.3% White 11.1% other/unknown Or 4.4% Hispanic 86.7% Non-Hispanic 9.3% Unknown	2	/
Putri	2021	survey	109	Taiwan	44.95%	100% Asian	0.25	/
Liu	2020	cross-sectional study	675	China	53%	/	1	/
Tenforde	2020	cross-sectional study	292	USA	52%	34.8% White, non-Hispanic 17% Black, non-Hispanic 36.3% Hispanic 11.9% other	0.5	p=0.01
Sykes	2021	cross-sectional study	134	UK	34.3%	91% White 1.5% Black	4	/

						6% Asian 1.5% Mixed/other		
Townsend	2021	cohort study	40	Ireland	90%	/	5	/
Writing Committee for the COMEBAC Study Group, 2021	2021	cohort study	478	France	42.1%	/	4	/
Augustin	2021	cohort study	353	Germany	53.5%	/	7	/
Duncan	2021	survey	NA	Scotland	/	/	/	/
Osikomaiya	2021	cohort study	274	Nigeria	33.9%	/	0.5	/
Orrù	2021	cross-sectional study	152	Italy	/	/	3 +	insomnia p<0.05 quality of life p<0.05
Pujari	2021	cross-sectional study	94	India	26.6%	/	0.5	/
Frontera	2021	prospective study	382	US	35%	Hispanic 15%/22% Non-Hispanic 62%/59% Prefer not to answer 23%/19%	6	/
Holmes	2021	cohort study	27	Australia	/	/	6	/
Townsend	2020	longitudinal study	111	Ireland	63%	/	3	/
Estiri	2021	cohort study	57622	US	/	/	3-6, 6-9	/
Chevinsky	2021	cohort study	148892	US	57%	40.9% white 25.2% Black 2.4% Asian 21% Hispanic 10.6% others	1-4	/
Pereira	2021	cohort study	38	UK	84%	BAME group 37%	7	/
Romero-Duarte Á	2021	cross-sectional study	797	Spain	46.3%	/	6	/
Graham	2021	cohort study	50	USA	66%	88% White, 4% Black or African American, 4% Asian, 0% American Indian or Alaskan Native, 4% other Or Hispanic or Latino 12% Not Hispanic or Latino 88%	4	/
Trinkmann	2021	cross-sectional study	246	Germany	56.1%	/	2	p<0.01
Nguyen	2021	cohort study	125	France	55.2%	/	7	/
Vrillon	2021	cohort study	125	France	58.4%	/	0.7	/
Modi	2021	qualitative study	131	US	47%	71% white(non-Hispanic) 7% white(Hispanic) 8% black 2% Asian 1% American Indian 8% Multiracial 4% other (Hispanic)	6	/
Pasquini	2021	cross-sectional study	26	Italy	65.4%	/	4	/
Boscolo-Rizzo	2021	cohort study	183	Italy	54.6%	/	6	/
Capelli	2021	cohort study	55	Italy	64%	/	8	/
Yvonne	2020	cross-sectional study	2113	Netherlands and Belgium	85%	/	2	p<0.001
Raman	2021	cohort study	58	UK	41.4%	BAME group 22.4%	2	p<0.0001 to 0.044
Swapna Mandal	2020	cross-sectional study	384	UK	38%	38.8% British Caucasian 17.1% Other Caucasian 6.5% British Asian	2	p<0.0001 for all symptoms

						10.3% Other Asian 6.8% Black British 7.6% Other black 13.9% Other ethnicity		
Marcel S. Woo	2020	cross-sectional study	18	Germany	57.9%	/	3	/
Puntmann	2020	cohort study	100	France	47%	/	2.5	/
Bellan	2021	cohort study	238	Italy	59.7%	/	4	/
Stavem	2020	cross-sectional study	451	Norway	56%	/	3	p<0.001
Małek	2021	cohort study	26	Poland	81%	/	1.5	/
Printza	2020	cross-sectional study	90	Greece	41.1%	/	1	/

852

853 P-value (*): P-value <0.05 represents a significant improvement in symptoms at follow-up

854 time compared to onset.

855

Figure 1: PRISMA Flow Diagram




Figure 2: Summary of studies included in meta-analysis




Figure 2.1: Forest plots for general symptoms




Figure 2.2: Forest plots for neurological symptoms




Figure 2.3: Forest plots for mental health symptoms




Figure 2.4: Forest plots for cardiopulmonary symptoms




Figure 2.5: Forest plots for gastrointestinal symptoms





Figure 3: Forest plots of subgroup analysis


(1) Fatigue

(2) Headache




(3) Dyspnea


(4) Cough




(5) Smell dysfunction



(6) Taste dysfunction



(7) Chest pain



(8) Muscle pain







Figure 4: Funnel plots of eight symptoms (reported in more than 10 studies)
 (1) Fatigue (2) Headache




(3) Dyspnea




(4) Cough




(5) Smell dysfunction



(6) Taste dysfunction



(7) Chest pain



(8) Muscle pain






Figure 5: P-values for residual selection bias



(1) Fatigue

(2) Headache





(3) Dyspnea

(4) Cough



(5) Smell dysfunction

(6) Taste dysfunction



(7) Chest pain

(8) Muscle pain

